Big Pharmacy Held 2020 Business Appreciation Meeting
Release time:
2020-12-01
Major Pharmacy Held 2020 Business Appreciation Meeting
On November 27, Jianfeng Major Pharmacy held 2020 Order Meeting and Year-end Business Appreciation Meeting with the theme of "Walking Together, Grateful for You". More than 200 representatives of manufacturers and store managers gathered together to review the work in 2020 and look forward to the future development prospects. Huang Jinlong, deputy general manager of
group company and general manager of pharmaceutical company, and Jin Huazhong, Secretary of the Party committee of pharmaceutical company, attended the meeting. In his speech, Huang Jinlong expressed his gratitude to the new and old customers present for their support to the big pharmacy, and affirmed the work done by the big pharmacy in 2020 and the hard work of all employees. He said that the future of the pharmaceutical industry is still both opportunities and challenges. Large pharmacies must pay close attention to policy trends and adjust business strategies in a timely manner; strengthen their own training, improve professional service skills, and increase customer added value and adhesion; adapt to new trends and timely Adjust the variety structure; introduce new retail models, broaden sales channels, and expand market scale. Jianfeng pharmacy is the backbone enterprise of Jianfeng group. The group will unswervingly support the pharmacy to become stronger and bigger. It is hoped that the new and old customers present here will strengthen cooperation and achieve the best benefits. Xiang Shunjiao, general manager of Jianfeng Pharmacy, said in his thank-you speech that in the future, Jianfeng Pharmacy will further strengthen cooperation with suppliers to better serve the health cause for a win-win situation.
Taking the opportunity of holding a thank-you meeting, the pharmacy also invited more than 40 drug and medical device manufacturers such as Tianshili, Hu Qingyutang and Wantong Pharmaceutical to hold a product ordering meeting. The store managers of large pharmacies shuttled back and forth at the site of the ordering meeting, carefully asking about the products and ordering according to the needs of their stores. Representatives of various manufacturers enthusiastically introduced products and answered product questions in detail. After the order meeting, the manufacturers said that this year's order meeting was full and they were very satisfied with the arrangement of the large pharmacy and looked forward to continuing in the coming year.
In order to enliven the atmosphere of the thank-you meeting, the pharmacy has also prepared wonderful cultural programs such as female solo singing, singing and dancing, magic, etc. (Reporter Ni Yingzhen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page